Sarepta Therapeutics reported Q3 2026 revenue of US$381.35 million with a narrower net loss, and later raised the low end of its 2026 total net product revenue guidance by US$50 million to a range of US$1.25 billion to US$1.3 billion. The higher outlook leans on a stabilizing ELEVIDYS gene therapy business and a resilient PMO franchise, even as year-to-date revenue trails the prior period and Q3 earnings fell short of analyst expectations. This article examines how Sarepta Therapeutics'...
Motley Fool Press Release.
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta agreeing to pay US$39.0 million and receiving broad freedom to operate on AAVrh74-based gene therapies under specified patents. The settlement not only closes costly legal disputes but also removes a significant patent overhang on ELEVIDYS and related AAVrh74 programs, potentially clarifying Sarepta’s long-term gene...
Sarepta Therapeutics (NASDAQ:SRPT) outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat. Chie
Novartis stock sinks 13% after del-desiran phase 3 trial failed primary endpoints, sparking biotech selloff.
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CAMBRIDGE, Mass., August 31, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET.
Sarepta (SRPT) is rated hold: ELEVIDYS uptake faces friction and execution risk despite better profitability. Read here for a detailed investment analysis.
Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.
Sarepta Therapeutics stock has seen a steep share price decline over the past few years, yet on current market multiples it still screens as expensive rather than clearly cheap. With the valuation checks giving a mixed signal, investors are left weighing recent performance against the current pricing. The share price decline of around 84.7% over the past 3 years points to a company where expectations have reset sharply and long term holders have faced heavy losses. Future progress in Sarepta...
This is the newest page. Registered accounts read further back.